|
Medication at admission, n (%)
|
|
ACEI/ARB
|
500 (22.3)
|
246 (21.7)
|
254 (22.8)
|
0.535
|
|
DAPT
|
677 (30.1)
|
348 (30.7)
|
329 (29.5)
|
0.542
|
|
Aspirin
|
1192 (53.0)
|
598 (52.8)
|
594 (53.3)
|
0.797
|
|
P2Y12 inhibitors
|
718 (32.0)
|
371 (32.7)
|
347 (31.1)
|
0.417
|
|
β-Blocker
|
496 (22.1)
|
251 (22.2)
|
245 (22.0)
|
0.927
|
|
Statins
|
691 (30.8)
|
370 (32.7)
|
321 (28.8)
|
0.048
|
|
OHA
|
400 (17.8)
|
56 (4.9)
|
344 (30.9)
|
< 0.001
|
|
Insulin
|
218 (9.7)
|
13 (1.1)
|
205 (18.4)
|
< 0.001
|
|
Medication at discharge, n (%)
|
|
ACEI/ARB
|
1558 (69.3)
|
758 (66.9)
|
800 (71.8)
|
0.012
|
|
DAPT
|
2245 (99.9)
|
1133(100.0)
|
1112 (99.8)
|
0.154
|
|
Aspirin
|
2246 (100.0)
|
1133 (100.0)
|
1113(99.9)
|
0.313
|
|
P2Y12 inhibitors
|
2247 (100.0)
|
1133 (100.0)
|
1114 (100.0)
|
–
|
|
β-Blocker
|
2045 (91.0)
|
1024 (90.4)
|
1021 (91.7)
|
0.292
|
|
Statins
|
2195 (97.7)
|
1101 (97.2)
|
1094 (98.2)
|
0.105
|
|
OHA
|
396 (17.6)
|
56 (4.9)
|
340 (30.5)
|
< 0.001
|
|
Insulin
|
211 (9.4)
|
12 (1.1)
|
199 (17.9)
|
< 0.001
|
|
Angiographic data, n (%)
|
|
LM lesion
|
102 (4.5)
|
45 (4.0)
|
57 (5.1)
|
0.192
|
|
Multi-vessel lesion
|
1498 (66.7)
|
655 (57.8)
|
843 (75.7)
|
< 0.001
|
|
In-stent restenosis
|
124 (5.5)
|
47 (4.1)
|
77 (6.9)
|
0.004
|
|
Chronic total occlusion lesion
|
295 (13.1)
|
136 (12.0)
|
159 (14.3)
|
0.111
|
|
SYNTAX score
|
11.0 ± 5.4
|
10.0 ± 5.1
|
12.0 ± 5.5
|
< 0.001
|
|
Procedural information
|
|
Target vessel territory, n (%)
|
|
LM
|
60 (2.7)
|
31 (2.7)
|
29 (2.6)
|
0.845
|
|
LAD
|
1464 (65.2)
|
738 (65.1)
|
726 (65.2)
|
0.987
|
|
LCX
|
784 (34.9)
|
364 (32.1)
|
420 (37.7)
|
0.006
|
|
RCA
|
952 (42.4)
|
434 (38.3)
|
518 (46.5)
|
< 0.001
|
|
Complete revascularization, n (%)
|
1323 (58.9)
|
746 (65.8)
|
577 (51.8)
|
< 0.001
|
|
Number of DES
|
2.0 ± 1.3
|
1.9 ± 1.3
|
2.0 ± 1.3
|
0.022
|
